Provided by Tiger Fintech (Singapore) Pte. Ltd.

Esperion Therapeutics

1.20
-0.0100-0.83%
Post-market: 1.19-0.0100-0.83%18:42 EDT
Volume:1.67M
Turnover:2.00M
Market Cap:237.84M
PE:-1.49
High:1.21
Open:1.19
Low:1.18
Close:1.21
Loading ...

Esperion Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
02 May

Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?

Zacks
·
01 May

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Zacks
·
29 Apr

Esperion to Participate in The Citizens Life Sciences Conference

GlobeNewswire
·
25 Apr

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Apr

Press Release: Esperion to Report First Quarter 2025 Financial Results on May 6

Dow Jones
·
23 Apr

Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
22 Apr

Esperion Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
18 Apr

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

GlobeNewswire
·
10 Apr

UPM Raflatac becomes first labeling business to offer product footprints in customer quotes

PR Newswire
·
10 Apr

Esperion Therapeutics Price Target Maintained With a $5.00/Share by Needham

Dow Jones
·
08 Apr

Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?

Zacks
·
03 Apr

Esperion Appoints Robert E. Hoffman to Board of Directors

THOMSON REUTERS
·
01 Apr

Press Release: Esperion Appoints Robert E. Hoffman to Board of Directors

Dow Jones
·
01 Apr

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
24 Mar

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Mar

Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia

MT Newswires Live
·
20 Mar

Esperion aligns with U.S. FDA to initiate Phase 3 trials of bempedoic acid

TIPRANKS
·
20 Mar

Esperion Aligns With U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

THOMSON REUTERS
·
20 Mar

Esperion Therapeutics Inc - to Initiate Phase 3 Clinical Studies This Year

THOMSON REUTERS
·
20 Mar